Market closed
CRISPR/$CRSP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About CRISPR
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Ticker
$CRSP
Sector
Trading on
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
393
Website
CRISPR Metrics
BasicAdvanced
$4.3B
-
-$4.34
1.67
-
Price and volume
Market cap
$4.3B
Beta
1.67
52-week high
$91.10
52-week low
$36.52
Average daily volume
2.5M
Financial strength
Current ratio
22.068
Quick ratio
21.997
Long term debt to equity
10.683
Total debt to equity
11.578
Management effectiveness
Return on assets (TTM)
-13.04%
Return on equity (TTM)
-19.20%
Valuation
Price to revenue (TTM)
114.012
Price to book
2.24
Price to tangible book (TTM)
2.24
Price to free cash flow (TTM)
-29.405
Growth
Revenue change (TTM)
-89.95%
Earnings per share change (TTM)
123.79%
3-year revenue growth (CAGR)
-65.58%
3-year earnings per share growth (CAGR)
-2.61%
What the Analysts think about CRISPR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
CRISPR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRISPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRISPR News
AllArticlesVideos
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·1 week ago
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
Seeking Alpha·2 weeks ago
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CRISPR stock?
CRISPR (CRSP) has a market cap of $4.3B as of February 22, 2025.
What is the P/E ratio for CRISPR stock?
The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of February 22, 2025.
Does CRISPR stock pay dividends?
No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of February 22, 2025.
When is the next CRISPR dividend payment date?
CRISPR (CRSP) stock does not pay dividends to its shareholders.
What is the beta indicator for CRISPR?
CRISPR (CRSP) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.